Cel-sci (NYSEMKT: CVM)
Cel-sci Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cel-sci Company Info
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
News & Analysis
Why CEL-SCI Stock Soared Today
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
Will All End Well for This Popular Reddit Biotech?
Everything went the wrong way for Cel-Sci.
Can You Count on This Popular Reddit Cancer-Treatment Stock?
Big news is coming for CEL-SCI, and we don't know which way the stock will move.
Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment
Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
These stocks were huge winners last week. But can their momentum continue?
One Biotech Stock to Avoid
Our investing community's latest pick to avoid: Vical.
An Inside Look at Biotech Investing, Part 2
More on investing in "baby biotechs."
CEL-SCI Investors Cheer a Bit Too Loudly
Finally, a phase 3 trial for cancer therapy Multikine.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.